ipharmacenter Consulting services

Eli Lilly and Company has released a public advisory highlighting possible safety issues with compounded formulations that combine tirzepatide and vitamin B12.   Also read: Top 10 Pharmaceutical Companies by Revenue 2025: Best-Selling Drugs Analysis The testing revealed a chemical impurity generated by the interaction between vitamin B12 and compounded tirzepatide, and Lilly notes that there is no information on how this impurity behaves in humans over the short or long term.

Johnson & Johnson Reports Encouraging Early Results for Erda‑iDRS in Intermediate‑Risk Non-Muscle Invasive Bladder Cancer Johnson & Johnson unveiled promising data from a Phase 1, open-label, multicenter clinical trial investigating its novel intravesical drug-release system containing erdafitinib (known as Erda‑iDRS, formerly TAR‑210) in patients with intermediate‑ and high‑risk non–muscle‑invasive bladder cancer (NMIBC) whose tumors carry specific FGFR (fibroblast growth fa